Table 3.

Rotavirus Vaccine Effectiveness Estimates Against Rotavirus Gastroenteritis Hospitalization^a in US Commercially Insured Infants and Children 8–20 Months of Age, 2007–2010

Calendar Year by Effectiveness	Vaccinated With ≥1 Dose of RV5 or RV1, %	Vaccinated		Unvaccinated		Total (Vaccinated and Unvaccinated)		Vaccine Effectivenessb	95% CI
		No. of Events	Total No. of Children	No. of Events	Total No. of Children	No. of Events	Total No. of Children
Direct effectiveness
2007	51.3	3	68,380	60	64,929			87	58, 96
2008	65.9	23	175,890	91	91,051			87	80, 92
2009	80.3	22	250,035	74	61,218			92	87, 95
2010	85.9	8	254,377	13	41,946			90	75, 96
Indirect effectiveness
2007	51.3			60	64,929			14	−14, 36
2008	65.9			91	91,051			44	30, 55
2009	80.3			74	61,218			40	24, 53
2010	85.9			13	41,946			82	70, 90
Total effectiveness
2007	51.3	3	68,380					91	73, 97
2008	65.9	23	175,890					92	88, 95
2009	80.3	22	250,035					95	92, 97
2010	85.9	8	254,377					98	96, 99
Overall effectiveness
2007	51.3					63	133,309	40	20, 54
2008	65.9					114	266,941	75	69, 79
2009	80.3					96	311,253	83	79, 86
2010	85.9					21	296,323	96	93, 97

Abbreviations: CI, confidence interval; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine.

^a During the prevaccine period (2001–2005), there were 722 events among 277,899 children.

^b Adjusted for birth month and age using the formula, (1 – hazard ratio) × 100.